Population pharmacokinetic of nadroparin calcium (Fraxiparine®) in children hospitalised for open heart surgery

European Journal of Pharmaceutical Sciences

Volumn 8, Issue 2, 1999, Pages 119-125

  Laporte, Silvy ^a   Mismetti, Patrick ^a   Piquet, Pascal ^b   Doubine, Sylvie ^b   Touchot, Anita ^b   Decousus, Hervé ^a  

^a UNIVERSITY HOSPITAL OF SAINT ETIENNE   (France)

^b CENTRE CHIRURGICAL MARIE LANNELONGUE   (France)

Author keywords

Heart surgery; Heparin; NONMEM; Paediatrics; Population pharmacokinetic

Indexed keywords

BLOOD CLOTTING FACTOR 10A; NADROPARIN;

ARTICLE; CHILD; CLINICAL TRIAL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NEWBORN; OPEN HEART SURGERY; POPULATION DYNAMICS; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOEMBOLISM;

ANTICOAGULANTS; CARDIAC SURGICAL PROCEDURES; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; INFANT; INTESTINAL ABSORPTION; MALE; MODELS, BIOLOGICAL; NADROPARIN;

EID: 0032922228     PISSN: 09280987     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0928-0987(98)00064-5     Document Type: Article

References (15)

1. Beal S.L. Population pharmacokinetic data and parameter estimation based on their first two statistical moments. Drug Metab. Rev. 15:1984;173-193.
2. Beal, S.L., Sheiner, L.B., Boeckmann, A.J., 1993. NONMEM users guide. NONMEM Project Group, University of California, San Francisco, CA.
3. Buck J.R., Connors R.H., Coon W.W., Weintraub W.H., Wesley J.R., Coran A.G. Pulmonary embolism in children. J. Pediatr. Surg. 16:1981;385-391.
4. Evans D.A., Wilmott R.W. Pulmonary embolism in children. Pediatr. Clin. North Am. 41:1994;569-584.
5. Leizorovicz A., Haugh M.C., Chapuis F.R., Samama M.M., Boissel J.P. Low molecular weight heparin in prevention of perioperative thrombosis. Br. Med. J. 305:1992;913-920.
6. Long D., Koren G., James A. Ethics of drug studies in enfants: how many samples are required for accurate estimation of pharmacokinetic parameters in neonates? J. Pediatr. 111:1987;918-921.
7. Mandema J.W., Verotta D., Sheiner L.B. Building population pharmacokinetic-pharmacodynamic models. I. Models for covariate effects. J. Pharmacokinet. Biopharmacol. 20:1992;511-528.
8. Massicotte P., Adams M., Marzinotto V., Brooker L.A., Andrew M. Low-molecular-weight-heparin in pediatric patients with thrombotic disease: a dose-finding study. J. Pediatr. 128:1996;313-318.
9. Michelson A.D., Bovill E., Andrew M. Antithormbotic therapy in children. Chest. 108:1995;506S-522S.
10. Mismetti P., Laporte-Simitsidis S., Navarro C., Sié P., D'Azemar P., Necciari J., Duret J.P., Gaud C., Decousus H., Boneu B. Aging and venous thromboembolism influence the pharmacodynamics of the anti-factor Xa and anti-thrombin activities of a low molecular weight heparin (Nadroparin). Thromb. Haemost. 79:1998;1162-1165.
11. Nurmohamed M.T., Rosendaal F.R., Buller H.R., Dekker E., Hommes D.W., Vandenbroucke J.P., Briet E. Low-molecular-weight heparin versus standard heparin in general and orthopaedic surgery: a meta-analysis. Lancet. 340:1992;152-156.
12. SAS Institute Inc., 1990. SAS/Graph and SAS/Stat user's guide, version 6.11. SAS Institute, Cary, NC.
13. Schmidt B., Andrew M. Neonatal thrombotic disease: prevention, diagnosis, and treatment. J. Pediatr. 113:1988;407-410.
14. Sheiner L.B., Beal S.L. Some suggestions for measuring predictive performance. J. Pharmacokinet. Biopharmacol. 9:1981;503-512.
15. Sheiner L.B., Ludden T.M. Population pharmacokinetics/dynamics. Annu. Rev. Pharmacol. Toxicol. 32:1992;185-209.